Latest news

February 16, 9:06 AM

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $7 to $6.

1 minute read

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $16 Price Target

February 16, 8:45 AM

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $16 price target.

1 minute read

Karyopharm Therapeutics Q4 EPS $(0.43) Misses $(0.35) Estimate, Sales $33.58M Miss $35.12M Estimate

February 15, 8:32 AM

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.35) by 22.86 percent. This is a 193.48 percent decrease over earnings of $0.46 per

1 minute read

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $16

January 10, 7:09 AM

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $18 to $16.

9 minute read

Options

Stocks That Hit 52-Week Lows On Friday

December 23, 1:16 PM

OnFriday, 143 stocks hit new 52-week lows.

ACHR

18 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

December 22, 2:13 PM

Thursday's session saw 329 companies set new 52-week lows.

ABNB

17 minute read

Options

Stocks That Hit 52-Week Lows On Friday

December 16, 1:39 PM

During Friday's trading, 293 companies set new 52-week lows.

ACEL

8 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

December 14, 3:20 PM

On Wednesday, 115 stocks hit new 52-week lows.

ALLR

1 minute read

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

December 12, 8:14 AM

– A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 – – 57% of Transfusion Independent Patients Achieved Hemoglobin Stabilization – – Company to Host